Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Interest Receivables Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Accured Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding

Perspective Therapeutics (CATX) Shares Issued (2016 - 2026)

Perspective Therapeutics' Shares Issued history spans 16 years, with the latest figure at $290000.0 for Q1 2026.

On a quarterly basis, Shares Issued changed N/A to $290000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $290000.0, a 74.27% decrease, with the full-year FY2024 number at $1.3 million, changed N/A from a year prior.
Shares Issued hit $290000.0 in Q1 2026 for Perspective Therapeutics, up from -$371000.0 in the prior quarter.
Over the last five years, Shares Issued for CATX hit a ceiling of $642000.0 in Q3 2024 and a floor of -$56.3 million in Q2 2022.
Historically, Shares Issued has averaged -$4.2 million across 5 years, with a median of $128000.0 in 2024.
Biggest five-year swings in Shares Issued: surged 1233.33% in 2023 and later tumbled 203.92% in 2025.
Tracing CATX's Shares Issued over 5 years: stood at $30000.0 in 2022, then surged by 1233.33% to $400000.0 in 2023, then decreased by 10.75% to $357000.0 in 2024, then tumbled by 203.92% to -$371000.0 in 2025, then skyrocketed by 178.17% to $290000.0 in 2026.
Business Quant data shows Shares Issued for CATX at $290000.0 in Q1 2026, -$371000.0 in Q4 2025, and $226000.0 in Q3 2025.